Evidence map›Paper›PMID 39875900›Full record

ArticleOrphanet journal of rare diseases2025

Identification of strengths and weaknesses of the healthcare system for persons living with rare diseases in Catalonia (Spain), and recommendations to improve its comprehensive attention: the "acERca las enfermedades raras" project.

José Hernández-Rodríguez, Fernando Martínez-Valle, Xènia Acebes, Carmen Alerany, Jordi Antón, Gonzalo Calvo, Marian Corral, Jordi Cruz, M Antònia Mangues-Bafalluy, José Mateo and 8 more

Abstract read
In one paragraph

Article in Orphanet journal of rare diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Friedreich's ataxia patient pathway in Europe.Frontiers in health services · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

José Hernández-Rodríguez *Clínic Program for Rare Diseases, Department of Autoimmune Diseases, Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain.ORCID http://orcid.org/0000-0002-2357-2015
Fernando Martínez-Valle *Division of Systemic Autoimmune Diseases, Internal Medicine Department, Hospital Universitari Vall d'Hebron, Barcelona, Spain.ORCID http://orcid.org/0000-0003-2673-2034
Xènia AcebesHealthCare Management Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.ORCID https://orcid.org/0000-0001-6449-938X
Carmen AleranyPharmacy Department, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
Jordi AntónPediatric Rheumatology Department, Hospital Sant Joan de Déu, Department of Surgery, Medical-Surgical Specialties and Pediatrics, University of Barcelona, Institut de Recerca Sant Joan de Déu, Barcelona, Spain.ORCID http://orcid.org/0000-0002-8792-4219
Gonzalo CalvoDepartment of Clinical Pharmacology, Area del Medicament, Hospital Clinic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.ORCID http://orcid.org/0000-0001-8860-6653
Marian CorralAsociación Española de Laboratorios de Medicamentos Huérfanos y Ultrahuérfanos (AELMHU), Barcelona, Spain.
Jordi CruzFEDER (Federación Española de Enfermedades Raras) Foundation, Madrid, Spain.
M Antònia Mangues-BafalluyPharmacy Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.ORCID http://orcid.org/0000-0002-1438-8515
José MateoThrombosis and Hemostasis Unit, Department of Hematology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.ORCID http://orcid.org/0000-0002-4227-3256
Josefa RiveraRare Diseases Unit, Parc Taulí University Hospital, Sabadell, Barcelona, Spain.
Albert SalazarHealth Services Research Group, General Management, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
Roser FranciscoRare Diseases Program, Catalan Health Service and Ministry of Health, Generalitat de Catalunya, Barcelona, Spain.
Cristina MallolRare Diseases Program, Catalan Health Service and Ministry of Health, Generalitat de Catalunya, Barcelona, Spain.ORCID http://orcid.org/0000-0002-2920-9612
Rita Reig-ViaderRare Diseases Program, Catalan Health Service and Ministry of Health, Generalitat de Catalunya, Barcelona, Spain.ORCID http://orcid.org/0000-0002-6893-6177
Ariadna Tigri-SantiñaRare Diseases Program, Catalan Health Service and Ministry of Health, Generalitat de Catalunya, Barcelona, Spain.ORCID http://orcid.org/0000-0003-2765-0065
Assumpta RicartRare Diseases Program, Catalan Health Service and Ministry of Health, Generalitat de Catalunya, Barcelona, Spain.ORCID http://orcid.org/0000-0001-7697-8572
Francesc PalauLaboratory of Neurogenetics and Molecular Medicine, Center for Genomic Sciences in Medicine, Institut de Recerca Sant Joan de Déu, Únicas SJD Center, Hospital Sant Joan de Déu, Barcelona, Spain. francesc.palau@sjd.es.ORCID http://orcid.org/0000-0002-8635-5421

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRare diseases (RDs) are a heterogeneous group of complex and low-prevalence conditions in which the time to establish a definitive diagnosis is often too long. In addition, for most RDs, few to no treatments are available and it is often difficult to find a specialized care team.

objectivesThe project "acERca las enfermedades raras" (in English: "bringing RDs closer") is an initiative primary designed to generate a consensus by a multidisciplinary group of experts to detect the strengths and weaknesses in the public healthcare system concerning the comprehensive care of persons living with a RD (PLWRD) in the region of Catalonia, Spain, where a Network of Clinical Expert Units (Xarxa d'Unitats de Expertesa Clínica or XUEC) was created and is being implemented since 2015. The additional primary aim was to propose recommendations to solve or improve the limitations found.

methodsA task force of 13 participants with multidisciplinary expertise on RDs completed a questionnaire and participated in two focus groups. A document was drafted with an item series of strengths and weaknesses of the healthcare system regarding the care of PLWRD, and a set of proposals or recommendations to overcome the problems identified.

resultsThe Catalan Government healthcare model of XUECs for the comprehensive care for RDs is currently valid and adapted to the needs of PLWRD and their families since its strategic optimal and operational framework, and it is aligned with the European Reference Networks (ERNs) thematic areas. The problems found in the current healthcare model were grouped into ten main areas: (1) the healthcare model for RDs; (2) coordination with primary healthcare providers and other tertiary and secondary hospitals; (3) access to and coordination with non-medical services; (4) the role of case manager in the XUEC; (5) genetic diagnosis; (6) undiagnosed patients; (7) treatments; (8) referring process, continuous follow-up, and transition from pediatric to adult centers; (9) research and education for professionals; and (10) associations of PLWRD and their families (patients' advocacy). The need for more resources was currently detected as the common factor for most of them. Ten key recommendations to improve the healthcare system regarding RDs were postulated.

conclusionsCatalonia has established a unique healthcare model for RDs in Spain, with clear strengths and advantages. However, after analyzing them, the experts suggested that new governmental political and administrative decisions are needed to ensure the efficient implementation of a healthcare plan for PLWRD in Catalonia, which could be applied to other regions and nations worldwide.

Indexed as

Delivery of Health CareRare DiseasesHumansSpainSurveys and QuestionnairesComprehensive careFocus groupHealthcare systemPatient journeyPerson living with a rare diseaseRare diseases

Identifiers

PMID39875900
PMCPMC11776278

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.